XTL 6865

Drug Profile

XTL 6865

Alternative Names: Anti-HCV dual monoclonal antibody - XTL Biopharmaceuticals; HepeX-C; XTL-6865

Latest Information Update: 01 Apr 2008

Price : $50

At a glance

  • Originator XTL Biopharmaceuticals
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 29 Mar 2007 Results from a phase I clinical trial in patients with chronic hepatitis C added to the adverse events and pharmacokinetics sections
  • 29 Mar 2007 XTL 6865 is available for licensing worldwide (http://www.xtlbio.com)
  • 15 Aug 2006 XTL is continuing enrolment in a phase I trial for Hepatitis C infection in the US and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top